SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934.
Date of Report: December 14, 2012
(Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
4902 Eisenhower Boulevard, Suite 125
|(Address of principal executive offices)||(Zip Code)|
(Registrants telephone number, including area code)
(Former Name or Former Address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Item 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
|(e)||Compensatory Arrangements of Certain Officers.|
On December 14, 2012, the Compensation Committee of the Board of Directors of Oragenics, Inc. (the Company) approved fiscal year-end cash incentive awards for 2012 for each of the Companys named executive officers currently employed with the Company in the amounts set forth below.
President and Chief Executive Officer
Chief Financial Officer
Vice-President, Research and Development
Dr. Bonfiglios bonus for 2012 was based upon the Committees determination that Dr. Bonfiglio has met certain of the previously established performance goals. The bonuses for Mr. Sullivan and Mr. Handfield were discretionary awards determined by the Committee. In addition, the Compensation Committee awarded an aggregate of $7,500 in discretionary cash bonuses to other employees.
In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 19th day of December, 2012.
|Chief Financial Officer|